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Background
Atopic dermatitis (AD) is a common skin disease of child-
hood which may cause debilitating symptoms and greatly
impair the quality of life of the patient and his relatives
[1]. Treatment of chronic AD usually focuses on topical
regimen of emolients and immunosuppressants, although
systemic immunosuppressive therapy is sometimes
required in more severe cases. Omalizumab is a huma-
nized monoclonal anti- IgE antibody that binds at the
high-affinity receptor (FcεRI) binding site that has revealed
some potential in the treatment of severe and recalcitrant
AD [2].
Case
Here, we present the case of a 11-years-old girl who has
been under treatment with Omalizumab for the past five
years. The patient first presented at 2 months of age with
a global and severe AD involving. She was severely atopic
with total IgE levels of 121,000, mild asthma, and multiple
food allergies. Treatment with oral prednisone, cyclos-
porin, azathioprine and intravenous immunoglobulins did
not improve her skin symptoms significantly. She was hos-
pitalised multiple times for skin infections attributed to
the disease and immunosuppressive medication. Treat-
ment with Omalizumab was initiated at 6 years of age.
Four months later, SCORAD index improved significantly.
Since, her follow-up has been almost free of any remark-
able event and treatment with Omalizumab has been well
tolerated.
Conclusion
Omalizumab should be considered as a potential treat-
ment in cases of severe AD resistant to classical therapy.
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